Skip to main content

PRA Health Sciences宣布任命新董事

Written by Customer Service on . Posted in Public Companies.

北卡罗来纳州罗利, Sept. 17, 2020 (GLOBE NEWSWIRE) — PRA Health Sciences, Inc.（NASDAQ:PRAH）今天宣布任命Glen Stettin为公司董事，任命自2020年9月14日起生效。
“我们很高兴Glen将加入我们的董事会。Stettin博士作为医生和高管广泛参与医疗保健领域的工作，他在创新、数据、分析、技术和综合健康解决方案方面的经验将为董事会提供宝贵的见解，帮助我们继续重塑临床研究，使其更易于为患者所用。”PRA Health Sciences, Inc.总裁、首席执行官兼董事会主席Colin Shannon表示。Stettin博士是Cigna Corporation旗下Express Scripts & Cigna Services的高级副总裁兼首席创新官，负责新临床解决方案和数据、分析以及平台即服务领域的研发、医患体验、产品开发和管理。在此之前，Stettin博士曾担任Express Scripts高级副总裁兼首席创新官，该公司于2018年被Cigna Corporation收购。Stettin博士在2012年4月Express Scripts与Medco Health Solutions, Inc.合并时加入了该公司。在Medco工作的17年中，他曾担任临床、运营、技术和产品组织领域的领导职务。Stettin博士拥有理海大学和宾夕法尼亚州医学院的学士及医学专业学位。他在加利福尼亚州大学旧金山分校完成了内科住院医师培训，还曾在Moffitt-Long Hospital担任内科住院总医师，并在加州大学旧金山分校和斯坦福大学任心脏科研究医师和罗伯特·伍德·约翰逊基金会临床学者。关于PRA Health Sciences按营业收入计，PRA Health Sciences是世界最大的全球合同研究机构之一，为生物技术和制药行业提供外包临床研发和数据解决方案服务。PRA全球临床研发平台遍及北美、欧洲、亚洲、拉丁美洲、南非、澳大利亚和中东，办公机构达到75个以上，全球员工超过17500人。2000年以来，PRA已参与了世界各地约4000项临床试验。此外，PRA还参与了众多关键性或支持性试验，超过95种产品由此获得了美国食品药品管理局和国际监管机构批准。要了解有关PRA的更多信息，请访问www.prahs.com。投资者关系咨询：InvestorRelations@prahs.com媒体咨询：Laurie Hurst，传播与公共关系总监
hurstlaurie@prahs.com | +1 (919) 786-8435

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.